REG - Oxford Biomedica PLC Aviva PLC - Holding(s) in Company <Origin Href="QuoteRef">AV.L</Origin> <Origin Href="QuoteRef">OXB.L</Origin>
RNS Number : 1396AOxford Biomedica PLC22 March 2017
For filings with the FCA include the annex
For filings with issuer exclude the annex
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi
1. Identity of the issuer or the underlying issuer
of existing shares to which voting rights are
attached:iiOxford Biomedica plc
2 Reason for the notification (please tick the appropriate box or boxes):
An acquisition or disposal of voting rights
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments
An event changing the breakdown of voting rights
Other (please specify):
3. Full name of person(s) subject to the
notification obligation:iiiAviva plc & its subsidiaries
4. Full name of shareholder(s)
(if different from 3.):ivRegistered Holder:
Chase (GA Group) Nominees Limited 202,248,884*
HSBC Global Custody Nominee (UK) Limited 38,838,403*State Street Nominees Limited 5,921,129*
*denotes direct interest
Chase (GA Group) Nominees Limited 17,681,614
Chase Nominees Limited 7,709,254
Vidacos Nominees Limited 12,132,128
5. Date of the transaction and date on
which the threshold is crossed or
reached:v16 March 2017
6. Date on which issuer notified:
17 March 2017
7. Threshold(s) that is/are crossed or
reached: vi, vii8% to 7% Change at Direct Interest Level (Box 8A)
8. Notified details:
A: Voting rights attached to sharesviii, ix
Class/type of
shares
if possible using
the ISIN CODESituation previous
to the triggering
transactionResulting situation after the triggering transaction
Number
of
SharesNumber
of
Voting
RightsNumber
of sharesNumber of voting
rights% of voting rights x
Direct
Direct xi
Indirect xii
Direct
Indirect
Ordinary Shares
GB00066458157293,797,657*
293,797,657*
284,531,412
247,008,416
37,522,996
7.998%
1.215%
* Includes Right to Recall Loaned Shares (5,791,351)
B: Qualifying Financial Instruments
Resulting situation after the triggering transaction
Type of financial
instrumentExpiration
date xiiiExercise/
Conversion Period xivNumber of voting
rights that may be
acquired if the
instrument is
exercised/ converted.% of voting
rightsRIGHT TO RECALL LOANED SHARES
N/A
N/A
8,191,351*
*DIRECT INTEREST
0.265%
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi
Resulting situation after the triggering transaction
Type of financial
instrumentExercise price
Expiration date xvii
Exercise/
Conversion period xviiiNumber of voting rights instrument refers to
% of voting rights xix, xx
Nominal
Delta
Total (A+B+C)
Number of voting rights
Percentage of voting rights
292,722,763
9.478%
9. Chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held, if applicable: xxiThe voting rights are managed and controlled by Aviva Investors Global Services Limited, with the following chain of controlled undertakings:-
Aviva Investors Global Services Limited:
Aviva plc (Parent Company)
Aviva Group Holdings Limited (wholly owned subsidiary of Aviva plc)
Aviva Investors Holdings Limited (wholly owned subsidiary of Aviva Group Holdings Limited)
Aviva Investors Global Services Limited (wholly owned subsidiary of Aviva Investors Holdings Limited)
Proxy Voting:
10. Name of the proxy holder:
See Section 4
11. Number of voting rights proxy holder will ceaseto hold:
12. Date on which proxy holder will cease to hold voting rights:
13. Additional information:
Figures are based the total number of voting rights of 3,088,217,926 as per the Company's Total Voting Rights Announcement of 1 March 2017.14. Contact name:
Tim Watts
15. Contact telephone number:
01865 783000
This information is provided by RNSThe company news service from the London Stock ExchangeENDHOLUASBRBUAOUAR
Recent news on Oxford BioMedica
See all newsRCS - Oxford Biomedica PLC - Launch of viral vector fast-track offering
AnnouncementREG - Oxford Biomedica PLC - Grant of Awards
AnnouncementREG - Oxford Biomedica PLC - Total Voting Rights
AnnouncementREG - Oxford Biomedica PLC - 2026 Annual General Meeting notification
AnnouncementREG - Oxford Biomedica PLC - Preliminary results for the year ended 31 Dec 2025
Announcement